Acadia Scraps Prader-Willi Drug After Late-Stage Failure
Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare neurological condition.
Acadia Scraps Prader-Willi Drug After Late-Stage Failure Read More »
